By analyzing E. coli protein levels, scientists found a surplus of membrane shuttle proteins that may play a role in ...

A Cornell University-led collaboration has uncovered the equipment that enables bacteria to survive exposure to antibiotics: ...

Cornell researchers have identified a key protein mechanism that helps bacteria expel antibiotics, making them more resistant ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

Research into developing new antimicrobial resistance treatment in Nigeria and other low/middle-income countries has fuelled ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Research into developing new antimicrobial resistance treatments in Nigeria and other low/middle-income countries has secured ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.